These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35089342)

  • 1. Analysis of the clinical characteristics of the liver injury induced by levetiracetam.
    Sun W; He Y; Li Z; Wang C
    J Pharm Pharmacol; 2022 Mar; 74(3):409-414. PubMed ID: 35089342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rare Case of Levetiracetam and Drug-Induced Idiopathic Aseptic Meningitis in a Pediatric Patient.
    McDonald D; Sultan R; Viswanathan A; Siu A
    Pharmacotherapy; 2019 Jan; 39(1):109-113. PubMed ID: 30488976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
    Li R; Zhou Q; Ou S; Wang Y; Li Y; Xia L; Pan S
    Epilepsy Res; 2020 Oct; 166():106408. PubMed ID: 32679487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam-Associated Psychogenic Non-epileptic Seizures; A Hidden Paradox.
    Jabeen SA; Gaddamanugu P; Cherian A; Mridula KM; Kumar DU; Meena AK
    J Popul Ther Clin Pharmacol; 2018 Jul; 25(2):e1-e11. PubMed ID: 30725538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute liver injury induced by levetiracetam and temozolomide co-treatment.
    Khoury T; Chen S; Abu Rmeileh A; Daher S; Yaari S; Benson AA; Cohen J; Mizrahi M
    Dig Liver Dis; 2017 Mar; 49(3):297-300. PubMed ID: 28034663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors predisposing to psychotic symptoms during levetiracetam therapy: A retrospective study.
    Pinckaers FME; Boon ME; Majoie MHJM
    Epilepsy Behav; 2019 Nov; 100(Pt A):106344. PubMed ID: 31525554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
    Kanemura H; Sano F; Aihara M
    Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biochemical characteristics, and outcome in 33 patients with ceftriaxone-induced liver injury.
    Feng CX; Ye WY; Shan QW
    Eur J Clin Pharmacol; 2024 Sep; 80(9):1317-1324. PubMed ID: 38809311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probable levetiracetam-related serum alkaline phosphatase elevation.
    Xiong N; Hou L; Lu N; Mohamed AA; Wang T; Huang Y
    BMC Neurol; 2012 Sep; 12():97. PubMed ID: 22994584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levetiracetam for neonatal seizures in preterm infants.
    Han JY; Moon CJ; Youn YA; Sung IK; Lee IG
    BMC Pediatr; 2018 Apr; 18(1):131. PubMed ID: 29636029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats.
    Smith C; Barnes Heller HL; Reif N; Van Hesteren M; Reinhart JM
    J Vet Intern Med; 2019 Mar; 33(2):827-830. PubMed ID: 30663797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
    Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
    J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of Drug-Induced Liver Injury Caused by Levetiracetam.
    Kawaguchi T; Tominaga T
    Asian J Neurosurg; 2019; 14(3):878-882. PubMed ID: 31497118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridoxine Add-On Treatment for the Control of Behavioral Adverse Effects Induced by Levetiracetam in Children: A Case-Control Prospective Study.
    Marino S; Vitaliti G; Marino SD; Pavone P; Provvidenti S; Romano C; Falsaperla R
    Ann Pharmacother; 2018 Jul; 52(7):645-649. PubMed ID: 29442544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
    Shukla G; Gupta A; Agarwal P; Poornima S
    Epilepsy Behav; 2016 Nov; 64(Pt A):216-218. PubMed ID: 27756024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
    Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
    Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous levetiracetam as treatment for status epilepticus.
    Berning S; Boesebeck F; van Baalen A; Kellinghaus C
    J Neurol; 2009 Oct; 256(10):1634-42. PubMed ID: 19458986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review.
    Moinuddin IA
    Am J Case Rep; 2020 Oct; 21():e926064. PubMed ID: 33112844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam in toxic seizures.
    Lee T; Warrick BJ; Sarangarm P; Alunday RL; Bussmann S; Smolinske SC; Seifert SA
    Clin Toxicol (Phila); 2018 Mar; 56(3):175-181. PubMed ID: 28753046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.